22 April 2021: The Federal Ministers give a final decision (positive with conditions) for this trial
File:
Trial reference:
Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of Nous-PEV, with pembrolizumab, in Patients with Unresectable Stage III / IV Cutaneous Melanoma and with Stage IV NSCLC